POS0513 ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS
Volume: 80, Issue: Suppl 1, Pages: 490 - 491
Published: May 19, 2021
Abstract
Background: Interstitial lung disease (ILD) is a severe complication of RA. Abatacept (ABA) have demonstrated efficacy in RA-ILD [1,2], although combined treatment with MTX or others DMARDs remain controversial. Objectives: To assess the efficacy and safety of ABA in monotherapy (ABA MONO ) versus combined-ABA, ABA plus MTX(ABA MTX ) or ABA plus other non-MTX DMARDs (ABA NON-MTX ), in RA-ILD. Methods: Observational multicenter study of RA-ILD...
Paper Details
Title
POS0513 ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS
Published Date
May 19, 2021
Volume
80
Issue
Suppl 1
Pages
490 - 491
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History